Specifically, three CDK4/6i, including Palbociclib, Ribociclib, and Abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer and are under evaluation in clinical trials for other cancers such as melanoma [13,14,15,16]. This evidence concerns the gene CDK4 and cancer.